We have a cure for hepatitis C. Why are hundreds of New Englanders still dying every year?
“Harriet Callahan was caught completely by surprise. While visiting a doctor for arthritis a few years ago, a routine blood test revealed she had hepatitis C, one of the deadliest infectious diseases in the United States. Callahan, in her 70s, was told it was likely the viral infection had been living silently in her bloodstream for decades.”
Among barriers to HCV care, the ‘real challenge’ is getting treatment to patients in need
“WASHINGTON — A special interest group session at The Liver Meeting focused on challenges in treating patients with hepatitis C virus, as well as disparities in access to care.”
Hawaii DOH recognizes nonprofit leader for ‘outstanding’ work in HIV/AIDS services
“HIV and hepatitis C counseling and testing, homeless outreach, … member of Oahu’s Homeless Coalition, and co-director of Hep Free Hawaii.”
AHF to Shame Gilead with Nationwide Protests on World AIDS Day
“Advocates target Gilead’s insatiable greed and its drug pricing and policies, including illegal restrictions the drug company places for certain pharmacies on access to 340B drug pricing for Gilead’s branded hepatitis C treatments.”
NHS set to eliminate Hepatitis C ahead of rest of the world
“The NHS is on track to eliminate Hepatitis C by 2025 thanks to a pioneering drug deal that is helping dramatically cut deaths – five years ahead of global targets. Following a five-year contract worth almost £1 billion to buy antiviral drugs for thousands of patients, deaths from Hepatitis C – including liver disease and cancer – have fallen by 35%.”
States split on hepatitis C restrictions
“A cure for hepatitis C is widely available. And yet, hundreds of New Englanders are still dying every year from related causes. Experts call the country’s response to the deadly bloodborne disease a “posterchild for health care disparities.”
HCV, HBV coinfection does not compromise HIV prognosis in the presence of active ART
“The study showed no significant difference in the immunologic and virologic responses of patients with HIV mono-infections had and patients with HIV/HBV and HIV/HCV coinfections,” the researchers said. “The study, therefore, concludes that, HIV/HBV and HIV/HCV coinfections do not significantly affect the immunologic and virologic responses of patients who have initiated highly active ART.”
